在不安腿综合征治疗中的多巴胺激动剂及其对睡眠参数的影响:系统性审查和元分析
Wei-Chih Yeh1, Ying-Sheng Li2, Yang-Pei Chang3
1Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Neurology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
Sleep medicine
|May 18, 2024
概括
多巴胺激动剂 (DAs) 在不安腿综合征 (RLS) 中改善睡眠效率,但可能会减少REM睡眠. 这一元分析阐明了DA对RLS睡眠架构的影响.
科学领域:
- 神经学 神经学
- 睡眠医学 睡眠医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 多巴胺激动剂 (DA) 是不安腿综合征 (RLS) 的标准治疗方法.
- 消化剂可以改变睡眠参数,可能导致不良影响.
- 了解DA对睡眠架构的影响对于RLS管理至关重要.
研究的目的:
- 澄清多巴胺激动剂 (DA) 对不安腿综合征 (RLS) 患者睡眠架构的影响.
- 分析快速眼动 (REM) 睡眠,慢波睡眠 (SWS) 和睡眠效率 (SE) 的变化.
主要方法:
- 一个系统的随机化安慰剂对照试验 (RCT) 的元分析,直到2023年10月.
- 在PubMed,Embase和Cochrane Central数据库中搜索相关的RCT.
- 分析了pramipexole,ropinirole和rotigotine对睡眠参数的影响,并根据治疗持续时间对子组进行分析.
主要成果:
- 普拉米醇改善了SE,但降低了REM睡眠百分比;罗皮尼罗尔也增强了SE.
- 罗提古丁没有显著影响SE或REM睡眠.
- 分析的DA都没有对SWS产生影响;短期使用罗皮尼罗尔会影响REM睡眠模式.
结论:
- 多巴胺激动剂显著影响RLS患者的睡眠参数.
- 特定的DA对睡眠效率和REM睡眠有不同的影响.
- 可能需要进一步的研究才能充分理解长期睡眠变化.
相关概念视频
Restless Leg Syndrome and Night Terrors
168
Restless Leg Syndrome (RLS), also known as Willis-Ekbom disease, is a neurological disorder characterized by an uncontrollable urge to move the legs due to uncomfortable sensations. These sensations typically occur during periods of rest or inactivity, particularly when lying down or sitting, and can severely disrupt sleep.
The exact cause of RLS is not fully understood, but it is believed to involve dopamine, a neurotransmitter that helps regulate muscle movement. Imbalances in dopamine levels...
The exact cause of RLS is not fully understood, but it is believed to involve dopamine, a neurotransmitter that helps regulate muscle movement. Imbalances in dopamine levels...
168
Sedatives and Hypnotics Drugs: Miscellaneous Agents
170
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
170
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
309
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
309
REM Sleep Behavior Disorder
181
REM Sleep Behavior Disorder (RBD) is a sleep disorder characterized by the absence of muscle paralysis that normally occurs during the REM phase of sleep. This absence allows individuals to physically act out their dreams, which are often vivid and disturbing. Common behaviors exhibited during episodes include kicking, punching, and yelling. These actions can be dangerous, potentially leading to injuries for the person with RBD or their bed partner.
RBD is significantly associated with...
RBD is significantly associated with...
181
Management of Insomnia
244
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
244
Parkinson's Disease: Treatment
261
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
261


